{
  "ticker": "VFY",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976849",
  "id": "02976849",
  "pages": 29,
  "price_sensitive": true,
  "date": "20250805",
  "time": "0833",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjppmrn4n3yw.pdf",
  "summary": "**Vitrafy Life Sciences Limited (ASX: VFY) \u2013 Financial Results Presentation FY25 (5 August 2025)**  \n\n### **Material Information Summary**  \n\n#### **Operational Highlights**  \n- **Technology Development**:  \n  - VCU2 hardware detailed design completed; build phase commenced.  \n  - Unregulated market product launch on track for Q2 FY26; regulated (medical device) launch expected H2 FY26 (USA).  \n  - LifeChain software upgrade progressing, with first release aligned to VCU2.  \n\n- **Commercial Progress**:  \n  - **Blood Platelets**:  \n    - Phase 1 study with U.S. Military (USAISR) completed, exceeding industry standards. Phase 2 to commence Q1 FY26.  \n  - **Cell & Gene Therapies**:  \n    - PBMC validation data shows 96% viability (vs. industry standard \u226570%). Engaging with potential partners.  \n  - **Aquaculture**:  \n    - Paid pilots with domestic providers; fertilisation results outperforming competitors (Vitrafy: 70.2% vs. competitor: 49.4%).  \n  - **Bovine**:  \n    - Post-thaw semen motility exceeding industry standards; collaboration with Select Sires, Inc. ongoing.  \n\n#### **Financial Highlights**  \n- **Revenue**: $65k (up 75% YoY), driven by aquaculture and grants.  \n- **Grant Income**: $4.8m Australian Industry Growth Fund grant awarded ($2.4m received, remainder deferred).  \n- **R&D Tax Incentive**: $983k (down from $2.0m YoY due to reduced eligibility).  \n- **Cash Position**: $29.6m (including $10.1m term deposits). Forecast runway through CY2027.  \n- **Loss**: Reported loss of $32.7m, but normalised loss at $11.3m after excluding non-cash items (e.g., $18.9m convertible note conversion cost).  \n\n#### **FY26 Outlook**  \n- **Market Development**: Focus on revenue-generating activities in animal reproduction, human health collaborations, and U.S. expansion.  \n- **Technology Milestones**:  \n  - Unregulated product launch (H1 FY26); medical device launch (H2 FY26).  \n  - Scale manufacturing and supply chain capacity.  \n\n#### **Key Risks/Monitors**  \n- Execution risk on VCU2 and LifeChain timelines.  \n- Regulatory approvals for medical device (U.S. H2 FY26).  \n- R&D spend to increase ~50% in FY26 (front-loaded in 1H).  \n\n---  \n**No material capital raising, trading halt, or corporate action details identified.**",
  "usage": {
    "prompt_tokens": 6122,
    "completion_tokens": 567,
    "total_tokens": 6689,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T23:05:07.688415"
}